Breast Cancer | Specialty

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Dr. Paplomata on the Role of Tucatinib/Trastuzumab/Capecitabine in HER2+ Metastatic Breast Cancer

October 19th 2020

Elisavet Paplomata, MD, discusses the role of tucatinib ​in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

FIP200 Deletion May Enhance Response to Immunotherapy in Breast Cancer

October 19th 2020

FIP200 deletion was found to enhance the efficacy of immune checkpoint inhibition in patients with nonresponsive breast cancer.

Dr. O’Regan on the Role of Therapy Escalation in HER2+ Breast Cancer

October 16th 2020

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

Tolaney Touches on HER2+ -Low Breast Cancer Testing, Possibilities, and Challenges

October 16th 2020

Sara M. Tolaney, MD, MPH, discusses the challenges in treating patients with heterogenous HER2 expression and what treatments could potentially improve outcomes for this subgroup.

Dr. Paplomata on Managing Trastuzumab Deruxtecan–Induced ILD in HER2+ Breast Cancer

October 13th 2020

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast Cancer

October 13th 2020

Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.

Family History Plays Key Role in Germline Testing for Hereditary Breast and Ovarian Cancers

October 12th 2020

Sofia D. Merajver, MD, PhD, discusses the importance of germline testing in patients with breast and ovarian cancer along with how this testing is being used to personalize treatment.

Dr. O’Regan on the Risk of Cardiomyopathy With Trastuzumab in HER2+ Breast Cancer

October 12th 2020

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

Dr. Gradishar on the Treatment Landscape in Metastatic HER2+ Breast Cancer

October 9th 2020

William J. Gradishar, MD, discusses the ​current treatment landscape in metastatic HER2-positive breast cancer.

Palbociclib Fails to Significantly Improve iDFS in Early Breast Cancer

October 9th 2020

Palbociclib was not found to significantly improve invasive disease-free survival in patients with hormone receptor–positive, HER2-negative early breast cancer who had residual disease following neoadjuvant chemotherapy.

Dr. Lin on Treatment Challenges in HER2+ Breast Cancer and Brain Metastases

October 8th 2020

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Dr. Burris on the Exploration of PARP Inhibitors in TNBC

October 8th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Immunomedics Acquisition Transfers Development of Sacituzumab Govitecan to Gilead Sciences

October 8th 2020

Gilead Sciences’ acquisition of Immunomedics, the manufacturer of sacituzumab govitecan-hziy, is expected to advance the development of the antibody-drug conjugate not only across additional types of breast cancer beyond triple-negative disease, but also in other solid tumors.

pCR Put Forth as a Surrogate Marker for Improved Survival in Early HER2+ Breast Cancer

October 8th 2020

Women with early-stage HER2-positive breast cancer who achieved a pathologic complete response to neoadjuvant HER2-directed therapy experienced prolonged event-free survival and overall survival versus those who did not.

Stakeholder Perspectives on the Rapidly Advancing Chemotherapy Landscapes for Triple-Negative Breast Cancer

October 8th 2020

In the metastatic breast cancer sphere, 2 chemotherapy agents have come to the forefront: capecitabine, for metastatic breast cancer, and eribulin, for triple-negative breast cancer.

Dr. Paplomata on the Clinical Impact of Tucatinib in HER2+ Breast Cancer

October 7th 2020

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

Assessing the Changing Treatment Landscape in Triple-Negative Breast Cancer

October 7th 2020

Treatment options for triple-negative breast cancer are historically limited; however, recent developments regarding the use of targeted therapies and various combination regimens have broadened the treatment spectrum and ushered in new clinical approaches.

Neratinib Shows Numerical OS Improvement in Early Stage HER2+ Breast Cancer

October 7th 2020

Neratinib was shown to have a numerical overall survival benefit in addition to improvements in invasive disease-free survival and central nervous system recurrence in patients with HER2-positive, hormone receptor–positive, early stage breast cancer.

Rapid Readouts: Phase 3 ASCENT Study

October 5th 2020